Clinical trials
Phase 3 Leukemia, Myeloid, Acute trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2010 | 5 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 8 |
| Active, not recruiting | 7 |
| Terminated | 7 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Ulm | 6 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 5 |
| AbbVie | 2 |
| Astex Pharmaceuticals, Inc. | 2 |
| Celgene | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Gilead Sciences | 2 |
| Pfizer | 2 |
| Boehringer Ingelheim | 1 |
| Cornerstone Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 39 |
| Leukemia | 5 |
| Leukemia, Erythroblastic, Acute | 2 |
| Leukemia, Megakaryoblastic, Acute | 2 |
| Leukemia, Monocytic, Acute | 2 |
| Leukemia, Myelomonocytic, Acute | 2 |
| Leukemia, Myelomonocytic, Chronic | 2 |
| Myelodysplastic Syndromes | 2 |
| Neoplasms | 2 |
| Congenital Abnormalities | 1 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.